Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

Philadelphia-based Endo sold its international pharma unit to Knight Therapeutics this week for up to $99 million, while Ireland-headquartered Mallinckrodt sold Therakos, a specialist in ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for 2seventy bio ...

The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

Rowley Law PLLC is investigating potential securities law violations by 2seventy bio, Inc. and its board of directors concerning the proposed acquisition of the company by Bristol Myers Squibb .